Paradoxical bronchodilator response is associated with increased risk of asthma exacerbations

J Allergy Clin Immunol Pract. 2024 Jul;12(7):1910-1913.e1. doi: 10.1016/j.jaip.2024.03.028. Epub 2024 Mar 26.

Authors

Affiliations

¹ Lerner Research Institute and Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
² Department of Medicine, University of Arizona, Tucson, Ariz.
³ Department of Pediatrics, Indiana University, Indianapolis, Ind.
⁴ Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
⁵ Department of Medicine, Mayo Clinic, Scottsdale, Ariz. Electronic address: Zein.Joe@mayo.edu.

PMID: 38548172
PMCID: PMC11238764 (available on 2025-07-01)
DOI: 10.1016/j.jaip.2024.03.028

No abstract available

Publication types

Letter

MeSH terms

Adult
Asthma* / drug therapy
Asthma* / epidemiology
Asthma* / physiopathology
Bronchodilator Agents* / therapeutic use
Disease Progression
Female
Humans
Male
Middle Aged
Risk

Substances

Bronchodilator Agents

Grants and funding